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The agonist-induced androgen receptor NH2- and
COOH-terminal (N/C) interaction is mediated by the
FXXLF and WXXLF NH2-terminal motifs. Here we dem-
onstrate that agonist-dependent transactivation of pros-
tate-specific antigen (PSA) and probasin enhancer/pro-
moter regions requires the N/C interaction, whereas the
sex-limited protein gene and mouse mammary tumor
virus long terminal repeat do not. Transactivation of
PSA and probasin response regions also depends on ac-
tivation function 1 (AF1) in the NH2-terminal region but
can be increased by binding an overexpressed p160 co-
activator to activation function 2 (AF2) in the ligand
binding domain. The dependence of the PSA and pro-
basin enhancer/promoters on the N/C interaction for
transactivation allowed us to demonstrate that in the
presence of androgen, the WXXLF motif with the se-
quence 433WHTLF437 contributes as an inhibitor to AR
transactivation. We further show that like the FXXLF
and LXXLL motifs, the WXXLF motif interacts in the
presence of androgen with AF2 in the ligand binding
domain. Sequence comparisons among species indicate
greater conservation of the FXXLF motif compared with
the WXXLF motif, paralleling the functional signifi-
cance of these binding motifs. The data provide evi-
dence for promoter-specific differences in the require-
ment for the androgen receptor N/C interaction and in
the contributions of AF1 and AF2 in androgen-induced
gene regulation.
Steroid receptors are ligand-activated transcription factors
that regulate gene activation through a series of events trig-
gered by high affinity hormone binding and mediated by recep-
tor binding to response element DNA and coactivators. At least
two domains have been identified that mediate nuclear recep-
tor interactions with coregulators. These are activation func-
tion 1 (AF1)1 in the NH2-terminal region and activation func-
tion 2 (AF2) in the ligand binding domain. The AF2 binding
surface in the ligand binding domain is comprised of helices 3,
4, and 12 and forms after hormone binding. For many nuclear
receptors, transactivation depends on AF2 recruitment of p160
coactivator complexes that have histone acetyl transferase ac-
tivity to modify chromatin structure (1). The p160 coactivators
are a group of proteins that include steroid receptor coactivator
1 (SRC1), transcriptional intermediary protein 2 (TIF2, GRIP1
or SRC2), and the steroid receptor coactivator 3 subfamily
(SRC3). Interaction with AF2 is mediated by the p160 coacti-
vator LXXLL motif that forms an amphipathic -helix and
binds the AF2 hydrophobic binding surface in the nuclear re-
ceptor ligand binding domain (2–5). For the androgen receptor
(AR), the functional importance of AF2 recruitment of p160
coactivators is unclear, with data implicating the AR NH2-
terminal AF1 region in AR-mediated gene activation.
The AF2 binding site in the AR ligand binding domain was
shown to mediate the agonist-induced NH2- and COOH-termi-
nal (N/C) interaction (6–10). Agonist-induced N/C interdomain
interactions are also reported for the estrogen (11) and proges-
terone receptors (12), but not for the glucocorticoid receptor
(GR) (7, 13). Two AR NH2-terminal LXXLL-like motifs that
interact with the AR ligand binding domain are the FXXLF and
WXXLF motifs (23FQNLF27 and 433WHTLF437) (14). Mutagen-
esis studies and mammalian two-hybrid and GST affinity ma-
trix assays demonstrated that the FXXLF motif interacts in the
presence of androgen with AF2 (14). However the site of inter-
action of the WXXLF motif was not determined, nor was it clear
whether interaction of the WXXLF motif depends on androgen
binding. In addition, previous studies made use of the MMTV
luciferase reporter vector, which may direct transcription
through mechanisms that differ from other androgen respon-
sive enhancer/promoters.
Here we show the functional importance of the AR N/C
interaction using androgen responsive enhancer/promoter re-
gions derived from the prostate specific antigen (PSA) and pro-
basin genes. Use of these responsive regions allowed us to dem-
onstrate, in addition, that the WXXLF motif inhibits recruitment
of TIF2 by the AF2 region but less than does the FXXLF motif.
Using a shorter NH2-terminal fragment than previously de-
scribed (14), we show that the WXXLF motif interacts in the
presence of androgen with the AF2 region of the ligand binding
domain. The data provide evidence that the AR N/C interaction is
required for AR-mediated regulation of two androgen-dependent
genes. The relatively high sequence conservation of the FXXLF
and WXXLF motifs among species further supports the func-
tional importance of the AR N/C interaction.
* The work was supported by Public Health Service Grant HD16910
from the National Institute of Child Health and Development, by coop-
erative agreement U54-HD35041 as part of the Specialized Cooperative
Centers Program in Reproductive Research of National Institutes of
Health; by the United States Army Medical Research and Material
Command Grant DAMD17-00-1-0094; and by the International Train-
ing and Research in Population and Health Program supported by the
Fogarty International Center and NICHD, National Institutes of
Health. The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
‡ To whom correspondence should be addressed: Laboratories for
Reproductive Biology, Rm. 374 Medical Sciences Research Bldg., CB
7500, University of North Carolina, Chapel Hill, NC 27599. Tel.: 919-
966-5168; Fax: 919-966-2203; E-mail: emw@med.unc.edu.
1 The abbreviations used are: AF1, activation function 1; AR, andro-
gen receptor; N/C, NH2-terminal and COOH-terminal; AF2, activation
function 2; TIF2, transcriptional intermediary factor 2; GST, glutathi-
one S-transferase; GR, glucocorticoid receptor; Luc, luciferase; PSA,
prostate-specific antigen; MMTV, mouse mammary tumor virus; DHT,
dihydrotestosterone.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 28, Issue of July 12, pp. 25631–25639, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 25631
This is an Open Access article under the CC BY license.
EXPERIMENTAL PROCEDURES
Plasmid Construction—GAL-peptide fusion proteins were con-
structed as described (15) and contain GAL4 DNA binding domain
residues 1–147 and the peptide sequences indicated. pcDNA3HA-
AR624–919 with wild-type AR sequence or with mutations K720A,
V716R, and E897K for in vitro translation were described (14). GSTAR-
(412–460) was created by amplifying the coding sequence in pCM-
VhAR, digesting the fragment with BamHI/EcoRI, and cloning the
fragment into pGEX3X digested with the same enzymes. GSTAR-(412–
460)WXXAA, where 433WHTLF437 is changed to WHTAA, was created
in the same manner except by amplifying using PCR the corresponding
region of the mutant pCMVhAR vector. AR-FXXAA, where 23FQNLF27
is changed to FQNAA, and AR-FXXAA/AXXAA, which in addition has
433WHTLF437 changed to AHTAA, were described (13, 15). AR-AXXAA
(AR-433AHTAA437) was created by amplifying using PCR the coding
sequence in pCMVhAR between BstEII and HindIII using a 5 mutant
oligonucleotide primer. The fragment was inserted into pCMVhAR di-
gested with the same enzymes. AR-FXXAA/AXXAA-K720A and AR-
FXXAA/AXXAA-E897K were created by digesting pCMVhAR-K720A
and pCMVhAR-E897K (10) with HindIII/XbaI and cloning the ligand
binding domain fragments into AR-FXXAA/AXXAA digested with the
same enzymes. AR-FXXAA/AXXAA(142–337) was created using a
double PCR mutagenesis strategy. The AR NH2-terminal region of
AR-FXXAA/AXXAA was amplified using a 5-primer preceding the Bgl-
II site, internal primers flanking the deleted region, and a primer 3 of
the BstEII site. The amplified fragments were digested with BglII/
BstEII and cloned into AR-FXXAA/AXXAA digested with the same
enzymes. DNA amplification by PCR was performed using Vent-polym-
erase (New England BioLabs). All regions of DNA that were amplified
using PCR were sequenced to verify the absence of random errors. The
human GR vectors GR(LXXLL)3 and GR(LXXAA)3 were described (13).
PSA-61-luciferase (PSA61-Luc), which contains a 5.8-kb androgen re-
sponsive enhancer/promoter region was provided by Jan Trapman,
Erasmus University, Rotterdam, The Netherlands. pGC9-Luc
(pGC9-Luc) that contains the 120-bp sex-limited protein androgen
responsive enhancer was provided by Diane M. Robins, University of
Michigan. BH500-Luc (probasin-Luc), which contains the 454-bp andro-
gen responsive probasin enhancer/promoter was provided by Robert J.
Matusik, Vanderbilt University. Mouse mammary tumor virus
(MMTV)-Luc was provided by Ronald M. Evans, the Salk Institute for
Biological Studies. The pSG5 mammalian expression vector for TIF2
was provided by Hinrich Gronemeyer, University of Louis Pasteur,
Strasbourg, France. 5XGAL4Luc3 was provided by Donald P. McDon-
nell, Duke University.
Transient Transfection Assay—Monkey kidney CV1 cells were main-
tained in Dulbecco’s modified Eagle’s medium containing 20 mM Hepes,
pH 7.2, penicillin/streptomycin, and 2 mM L-glutamine. Cells were
transfected with wild-type and mutant AR expression vectors and lu-
ciferase reporter vectors using the calcium phosphate DNA precipita-
tion method (13). 50 ng of wild-type and mutant pCMVhAR vectors
were cotransfected with 5 g of MMTV-Luc or 2 g of pGC9-Luc per
6-cm dish plated the day before at 0.42  106 cells/dish. 100 ng of
wild-type and mutant pCMVhAR vectors were expressed with 5 g of
PSA61-Luc or 5 g probasin-Luc. Cells were incubated in serum-free,
phenol red-free media for 40 h with or without hormone as indicated.
Cells were harvested in 0.5 ml of 25 mM Tris phosphate, pH 7.8, 2 mM
EDTA, 1% Triton X-100, and 100 l was analyzed using an automated
LumiStar Galaxy (BMG Labtechnologies) multiwell plate reader
luminometer.
Two-hybrid Peptide Interaction Assay—Human epithelioid cervical
carcinoma HeLa cells were maintained in Eagle’s minimum essential
medium (Invitrogen) supplemented with 10% fetal bovine serum (Hy-
clone) and 2 mM L-glutamine and penicillin/streptomycin. Cells were
plated in 12-well plates at 0.1  106 cells/well and transfected using per
well 0.05 g of wild-type or mutant pCMVhAR, 0.15 g of GAL-peptide,
and 0.1 g of 5XGAL4Luc3. After plating and incubating overnight, the
cells were placed in 0.8 ml of fresh media containing serum and addi-
tives and transfected by the Effectine method (Qiagen) using per well:
75 l of EC buffer, 1 l of enhancer, 1 l of Effectine reagent, and 400
l of media containing 10% serum and additives. The DNA transfection
mix was typically prepared for 4 wells/tube. After 24 h, cells were
washed in phosphate-buffered saline, and 2 ml of serum-free media
lacking phenol red was added per well. Cells were incubated for 24 h in
the absence and presence of the indicated hormones and assayed for
luciferase activity as described above except harvested in 0.22 ml of
lysis buffer/well.
In Vitro Protein Interaction Assay—GST fusion proteins were ex-
pressed in XL1-Blue Escherichia coli cells treated with 0.5 mM isopropyl
-D-thiogalactopyranoside and extracted and incubated with glutathi-
one-agarose beads (Amersham Biosciences) as described (14). In vitro
translated proteins were labeled in the presence of 25 Ci of [35S]me-
thionine (PerkinElmer Life Sciences) using the TNT T7 Quick Coupled
transcription/translation system (Promega) in the presence and ab-
sence of 1 M dihydrotestosterone (DHT). Washed beads were boiled in
SDS buffer and input lanes contained 10% of the binding reactions.
RESULTS
Response Element Specificity of the WXXLF and FXXLF Mo-
tif-mediated N/C Interaction and Coactivation by TIF2—We
investigated whether androgen response regions derived from
different enhancer/promoter regions have a similar require-
ment for the androgen-induced N/C interaction in AR-mediated
gene regulation. Luciferase reporter vectors were tested that
contain enhancer/promoter regions from the androgen-regu-
lated genes, PSA (16, 17), probasin (18), sex-limited protein
(pGC9) (19, 20), and MMTV (21–23). The role of the WXXLF
and FXXLF motifs and effects of TIF2 coactivation on lucifer-
ase activity were determined using wild-type AR (AR-FXXLF/
WXXLF) or AR in which FXXLF was changed to FXXAA,
WXXLF was changed to AXXAA, or both mutations were cre-
ated in the same protein.
AR transactivation of the PSA and probasin enhancer/pro-
moter regions (Fig. 1A) and the pGC9 and MMTV promoters
(Fig. 1B) was increased 2–3-fold by TIF2 coexpression. Muta-
tion of the FXXLF motif (AR-FXXAA/WXXLF) decreased to low
levels transactivation of the PSA and probasin luciferase re-
porters in the absence of TIF2 coexpression (Fig. 1A). This
decrease in activity was recovered by coexpression of TIF2. In
contrast, mutation of the FXXLF motif had no major effect on
transactivation of the MMTV-Luc and pGC9-Luc enhancer/
promoters in the absence of TIF2 coexpression (Fig. 1B). Sur-
prisingly, mutation of the WXXLF motif alone (AR-FXXLF/
AXXAA) increased the response of the PSA and probasin
enhancer/promoters, which was increased further by TIF2 co-
expression (Fig. 1A). In contrast, mutation of WXXLF had
relatively little effect on the response of MMTV-Luc and
pGC9-Luc (Fig. 1B). Mutating both binding motifs (AR-
FXXAA/AXXAA) decreased transactivation of the PSA and pro-
basin enhancer/promoters, which was rescued by coexpression
of TIF2 (Fig. 1A), again with relatively little effect on the
pGC9 and MMTV promoters.
The results indicate that in contrast to the pGC9 and
MMTV enhancer/promoters, androgen regulation of the PSA
and probasin enhancer/promoter regions depends on the AR
N/C interaction mediated by the FXXLF and WXXLF motifs in
the presence of androgen. The increase in transactivation by
mutating WXXLF alone suggests an inhibitory role of this
motif in AR activity, whereas a decrease in transactivation by
the FXXAA and FXXAA/AXXAA mutants indicates a strong
requirement for the N/C interaction. The results are in agree-
ment with the FXXLF motif primarily mediating the N/C in-
teraction, whereas mutation of the WXXLF motif alone does
not abolish the N/C interaction (14). The detrimental effect on
transactivation of losing the N/C interaction was recovered by
TIF2 overexpression. The results support previous evidence
from androgen insensitivity syndrome mutations (9) where the
N/C interaction is critical for AR-mediated transactivation of
androgen-dependent genes in vivo.
We investigated further the inhibitory effect of the WXXLF
motif in AR-mediated transactivation of the PSA enhancer/
promoter by mutating the WXXLF and FXXLF binding motifs
in an AR mutant in which the NH2-terminal AF1 residues
142–337 were deleted. Deletion of AF1 resulted in nearly back-
ground levels of activity in the absence or presence of TIF2
coexpression (Fig. 2), indicating an important role for AF1 in
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AR-mediated transactivation. Introducing mutations into the
FXXLF (AR-FXXAA142–337) and FXXLF plus WXXLF mo-
tifs (AR-FXXAA/AXXAA142–337) increased AR-mediated
transactivation of the PSA61-Luc reporter in the absence and
presence of TIF2 coexpression. When the WXXLF motif alone
was mutated in the AF1 deletion mutant (AR-FXXLF/
AXXAA142–337, Fig. 2), there was only a small increase in
transactivation by TIF2. Essentially identical results were ob-
tained using the probasin-Luc reporter (data not shown).
We conclude that in the absence of AF1, both FXXLF and
WXXLF motifs have a small inhibitory effect on AR transacti-
vation in the absence of TIF2 coexpression. There was a syn-
ergistic inhibitory effect by both motifs, possibly reflecting in-
hibition of endogenous TIF2 coactivation through AF2 in the
ligand binding domain. The greater level of TIF2-stimulated
luciferase activity observed with the FXXLF mutant compared
with the WXXLF mutant indicates that FXXLF more effec-
tively inhibits AR-mediated gene activation by TIF2 than does
FIG. 1. Requirements for the N/C in-
teraction and TIF2 coactivation by
different androgen responsive en-
hancer/promoters. Androgen-induced
luciferase activity was determined using
the PSA61-Luc and probasin-Luc reporter
vectors (A), and the pGC9-Luc and
MMTV-Luc reporter vectors (B) in the ab-
sence and presence of TIF2 coexpression.
CV1 cells were transfected using calcium
phosphate DNA precipitation as de-
scribed under “Experimental Procedures”
with (per 6-cm dish) 50 ng of pCMVhAR
plus 2 g of pGC9-Luc or 5 g of MMTV-
Luc, or 100 ng of pCMVhAR with 5 g of
PSA61-Luc or 5 g of probasin-Luc. pCM-
VhAR had the wild-type sequence (AR-
FXXLF/WXXLF) or had mutations in the
FXXLF (AR-FXXAA/WXXLF), WXXLF
(AR-FXXLF/AXXAA), or both motifs (AR-
FXXAA/AXXAA) and was assayed in the
absence and presence of 5 g of pSG5-
TIF2. Cells were incubated for 40 h in the
absence and presence of 1 nM DHT, and
luciferase activity was determined. The
data are representative of at least three
independent experiments.
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WXXLF. The TIF2-stimulated increase in luciferase activity of
the double mutant provides further evidence that the WXXLF
motif contributes to inhibiting coactivation by TIF2 even
though mutagenesis of the WXXLF motif itself did not effec-
tively increase transactivation by TIF2. Enhancement of PSA
and probasin luciferase activity observed with the WXXLF
mutant alone (Fig. 1A) appeared to depend on AF1 because the
increase in activity was less apparent when the WXXLF mu-
tant was combined in the AF1 deletion mutant.
Enhancer/Promoter Requirements for the N/C Interaction
Using a Receptor Chimera—To evaluate further the require-
ment for the N/C interaction in transactivation of the PSA
enhancer/promoter region versus the MMTV promoter, we
made use of a previously described GR chimera GR(LXXLL)3 in
which an artificial N/C interaction was introduced (13).
GR(LXXLL)3 contains the 3 LXXLL motif region of TIF2 that
interacts in the presence of dexamethasone with the GR ligand
binding domain AF2 region and results in a 5-fold slower dis-
sociation half-time of [3H]dexamethasone compared with wild-
type GR. In the presence of 1 or 10 nM dexamethasone, GR
stimulated the PSA (Fig. 3A) and probasin reporters (data not
shown), and the MMTV (Fig. 3B) and pGC9 luciferase report-
ers (data not shown), with the weakest response from pGC9.
GR(LXXLL)3 caused greater ligand-induced transactivation of
the PSA61-Luc reporter than did GR, or GR(LXXAA)3 in which
the 3 LXXLL motifs were mutated to LXXAA (Fig. 3A). Similar
increases in gene activation by GR(LXXLL)3 were observed
using the probasin-Luc and pGC9-Luc reporters (data not
shown). In contrast, response of the MMTV-luciferase reporter
was similar for GR and the GR chimeras (Fig. 3B). The results
support observations above that transactivation of the andro-
gen responsive enhancer/promoters from PSA and probasin
depend on an agonist-induced N/C interaction for optimal
transactivation compared with the MMTV enhancer/promoter.
The increased response of pGC9-Luc to GR(LXXLL)3 suggests
that it shares some properties of PSA and probasin response
elements that are sensitive to the effects of an N/C interaction.
TIF2 Coactivation of AR-mediated Transactivation of the
PSA Reporter Requires Recruitment by AF2—We next investi-
gated whether the increase in AR transactivation of PSA61-Luc
(Fig. 4A) and probasin-Luc by TIF2 required TIF2 binding to
the AF2 region of the ligand binding domain. In contrast to
TIF2, TIF2m123, a mutant in which the 3 LXXLL motifs were
changed to LXXAA, was unable to coactivate AR or the AR N/C
interaction mutants using the PSA61-Luc reporter (Fig. 4A).
Transactivation in the presence of TIF2m123 was less than the
control without TIF2 coexpression. Similar results were ob-
served using the probasin and MMTV-Luc reporters (data not
FIG. 2. Role of the WXXLF and FXXLF motifs in inhibiting
TIF2 coactivation of the PSA enhancer/promoter by an AR AF1
deletion mutant. Androgen induction of the PSA61-Luc reporter vec-
tor was determined by transfecting CV1 cells with pCMVhAR142–337
lacking the AF1 transactivation residues 142–337, which had the wild-
type binding motif sequence (AR-FXXLF/WXXLF142–337) or the FXXLF
(AR-FXXAA/WXXLF142–337), WXXLF (AR-FXXLF/AXXAA142–337),
or both motifs were mutated (AR-FXXAA/AXXAA142–337). Incubations
were performed in the absence and presence of coexpression of pSG5-TIF2
(5 g) and 1 nM DHT as indicated. The data are representative of at least
three independent experiments.
FIG. 3. Requirement for the N/C in-
teraction in transactivation by dif-
ferent enhancer/promoters using a
TIF2-GR chimera. Dexamethasone-in-
duced activation of PSA61-Luc (A) and
MMTV-Luc (B) was determined in CV1
cells as described under “Experimental
Procedures.” Cells were transfected with
100 ng (for PSA61-Luc) and 50 ng (for
MMTV-Luc) with pCMVhGR (GR) or the
TIF2-pCMVhGR chimera TIF2-(627–
780)-GR-(2–777) containing wild-type
LXXLL ((LXXLL)3GR) or LXXAA mutant
sequence ((LXXAA)3GR) in the absence
and presence of 1 and 10 nM dexametha-
sone (DEX). The 627–780 region of TIF2
contains 3 LXXLL motifs. Luciferase ac-
tivity shown is representative of at least
three independent experiments.
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shown). The data suggest that coactivation by TIF2 of each of
the enhance/promoters requires interaction of the TIF2 LXXLL
motifs with the AR AF2 region and that TIF2m123 acts to a
limited extent as a dominant negative inhibitor of endogenous
TIF2. The lack of coactivation by TIF2m123 suggests, in addi-
tion, that an interaction between other regions of TIF2 and the
AR NH2-terminal region (10, 30, 31) were not sufficient to
mediate increased transactivation.
A specific role for AF2 in AR transactivation of the PSA61-
Luc reporter by TIF2 was investigated using two AR AF2
mutants. Lysine 720 in helix 3 of the ligand binding domain is
critical for TIF2 coactivator LXXLL motif binding, but not for
the binding of the AR NH2-terminal FXXLF motif (14). Glu-
tamic acid 897 in helix 12 of the ligand binding domain is
required for both TIF2 LXXLL motif binding and the N/C inter-
actions (14). AR-FXXLF/WXXLF-K720A did not decrease AR-
mediated transactivation of the PSA61-Luc reporter in the ab-
sence of TIF2 expression but blocked coactivation by TIF2 (Fig.
4B). AR-FXXLF/WXXLF-E897K reduced inherent AR activity
and blocked coactivation by TIF2. Furthermore, AR transactiva-
tion was not stimulated by TIF2 when AR had either of these
AF2 mutations and where the N/C interaction was interrupted
by mutations in the FXXLF and WXXLF motifs. The results
indicate that TIF2 coactivation of AR requires binding to AF2.
Androgen Dependence of the WXXLF Motif Interaction with
AF2—Previously we used a GST affinity matrix assay to deter-
mine the effect of androgen on the interaction of the FXXLF
and WXXLF motifs with the ligand binding domain. We dem-
onstrated an androgen-dependent interaction of the FXXLF
motif with AF2, but results with the WXXLF motif were incon-
clusive (14). Extensive binding in the absence of androgen of a
233-amino acid ARGST fusion peptide containing the WXXLF
motif raised the possibility that some of the binding was non-
specific (14). We therefore prepared a fusion peptide with a
shorter sequence containing the WXXLF motif. GSTAR-(412–
460) bound 3-fold higher levels of 35S-labeled AR ligand binding
domain residues 624–919 in the presence than in the absence
of DHT (Fig. 5A, lanes 4 and 5). In addition, mutation of
residues LF to AA in the WXXLF motif in GSTAR-(412–
460)WXXAA eliminated the androgen-dependent interaction
(Fig. 5A, lanes 6 and 7). The results indicate that the WXXLF
motif binds the AR ligand binding domain in an androgen-de-
pendent manner.
The predicted amphipathic -helical structure of the WXXLF
sequence and the hormone dependence of its interaction with
the ligand binding domain suggested that the WXXLF motif
interacts with the AF2 binding surface. We tested a series of
AF2 mutants that were shown previously to decrease or elim-
inate TIF2 LXXLL motif binding (4, 5, 10) and the binding of
the AR FXXLF motif in the N/C interaction (10, 14). AR AF2
mutations E897K, V716R and K720A introduced into the 35S-
labeled ligand binding domain each reduced or eliminated
FIG. 4. Interaction of TIF2 with AF2
in AR-mediated transactivation of
the PSA enhancer/promoter. Andro-
gen-induced activation of PSA61-Luc was
determined in CV1 cells transfected with
100 ng of wild-type pCMVhAR without
(AR-FXXLF/WXXLF) and with mutations
in the FXXLF (AR-FXXAA/WXXLF),
WXXLF (AR-FXXLF/AXXAA), and both
motifs (AR-FXXAA/AXXAA). In A, cells
were coexpressed without or with 5 g of
pSG5TIF2 or 5 g of pSG5TIF2m123,
where the 3 LXXLL motifs were mutated
to LXXAA (4). In B, the FXXLF and
WXXLF binding motifs were wild-type or
mutant and were alone or combined with
K720A and E897K mutations in the AF2
region of the ligand binding domain. Lu-
ciferase activity was determined in the
absence and presence of 1 nM DHT and is
representative of at least three independ-
ent experiments.
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androgen-dependent binding of GSTAR-(412–460) (Fig. 5A,
lanes 9–22). Signal intensity of the wild-type control in the
presence of androgen was 2-, 3-, and 4.5-fold greater than that
of the E897K, V716R, and K720A mutants, respectively, in the
presence of androgen, based on optical scanning of the film. The
E897K ligand binding domain fragment mediated a 2-fold in-
crease in binding of the WXXLF peptide in the presence of
androgen relative to the no hormone control, but no androgen
dependent increase in binding was detectable with the V716R
and K720A ligand binding domain. Residues Glu-897, Val-716,
and Lys-720 are part of the AF2 binding surface. The Val-716
side chain is in the AF2 hydrophobic cleft. Mutation to arginine
(V716R) disrupts the hydrophobic binding surface and, as also
shown previously in GST affinity matrix assays for FXXLF
motif binding (10), is more disruptive than the Glu-897 muta-
tion to WXXLF motif binding. The data provide evidence that
the WXXLF motif binds the AF2 region of the ligand binding
domain in an androgen-dependent manner.
To further substantiate the androgen-dependent binding of
the WXXLF motif to AF2, we used a peptide two-hybrid inter-
action assay previously described in HeLa cells (15). GAL4-
DNA binding domain fusion protein GALAR-(426–444) was
constructed to contain the GAL4 DNA binding domain and 19
amino acids of the WXXLF region. GALAR-(426–444) was
coexpressed with AR-FXXAA/AXXAA, an AR mutant in which
LF in both NH2-terminal binding motifs and Trp in the second
motif were changed to Ala to eliminate the FXXLF- and
WXXLF-mediated interdomain N/C interaction. GALAR-(426–
444) bound AR-FXXAA/AXXAA in the presence of androgen,
with an increase in luciferase activity greater than that ob-
served with AR-FXXAA/AXXAA alone (Fig. 5B). The extent of
interaction of the GALAR-(426–444) WXXLF peptide was less
than that observed with GALAR-(16–36), a fusion protein
containing the 21-amino acid region of the FXXLF motif
(Fig. 5B).
To confirm that AF2 in the AR ligand binding domain is the
binding site for the WXXLF motif, the two AF2 mutants de-
scribed above, AR-FXXAA/AXXAA-K720A and AR-FXXAA/
FIG. 5. Androgen-dependent binding of the WXXLF motif to the AF2 region of the ligand binding domain using GST affinity matrix
binding and mammalian two-hybrid peptide interaction assays. A, the GST fusion protein (GST-AR) lacking the AR sequence (0) or
GSTAR-(412–460) with wild-type WXXLF or WXXAA mutant sequence, were incubated as described under “Experimental Procedures” with
35S-labeled AR ligand binding domain residues 624–919 in the presence and absence of 1 M DHT. 35S-labeled AR-(624–919) had wild-type
sequence (WT) or contained AF2 mutations E897K, V716R, or K720A as indicated. 10% of the input radioactivity used in the binding reactions is
shown in lanes 1, 8, 13, and 18 (I). Migration of 35S-labeled AR-(624–919) is indicated by an arrow. B, peptide interaction assays were determined
in HeLa cells transfected as described under “Experimental Procedures” without the GAL4 vector (), or with GAL-0 lacking AR sequence (0),
GALAR-(16–36) containing AR amino acid residues 16–36 with the FXXLF motif, or GALAR-(426–444) containing AR amino acid residues
426–444 with the WXXLF motif. Cells were cotransfected with pCMVhAR that had mutations in the FXXLF and WXXLF motifs (AR-FXXAA/
AXXAA) in the absence or presence of AF2 mutations K720A or E897K as indicated. Incubations were performed for 24 h in the absence and
presence of 10 nM DHT. Luciferase activity is representative of at least three independent experiments.
Enhancer/Promoter Selectivity and the AR WXXLF Motif25636
AXXAA-E897K, were tested by peptide interaction. Binding of
the two peptides containing the WXXLF (GALAR-(426–444))
or FXXLF (GALAR-(16–36)) motifs was compared. AR-
FXXAA/AXXAA-K720A showed little interaction with
GALAR-(426–444) above background levels in the presence of
DHT (Fig. 5B). In contrast, GALAR-(16–36) containing the
FXXLF motif bound AR-FXXAA/AXXAA-K720A as indicated
by the increase in luciferase activity. Interaction with AR-
FXXAA/AXXAA-E897K was near background levels for both
the FXXLF and WXXLF fusion peptides (Fig. 5B). In studies
not shown, GALAR-(426–444) containing the WXXLF motif
interacted as well with wild-type AR as it did with AR-FXXAA/
AXXAA. However, it did not interact with AR-V716R, an addi-
tional AF2 mutant in which the NH2-terminal binding motifs
were not modified. None of the AF2 mutations caused a change
in the apparent equilibrium androgen binding affinity (10).
The results indicate androgen-dependent binding of the
WXXLF motif to the AF2 region of the ligand binding domain
that is weaker than that observed with the FXXLF motif. The
greater dependence of the WXXLF sequence on lysine 720
suggests slight differences in the AF2 binding surface for the
FXXLF and WXXLF sequences, where the binding site for
WXXLF more closely resembles the binding site requirements
for the TIF2 LXXLL motif (10).
DISCUSSION
Here we report that enhancer/promoter regions derived from
the PSA and probasin genes require the androgen-induced N/C
interaction for effective AR-mediated transactivation. This con-
trasts the enhancer/promoter region of MMTV that was rela-
tively nonselective with regard to the presence of the N/C
interaction for transactivation by AR. The dependence of the
enhancer/promoter regions of the PSA and probasin genes on
the N/C interaction allowed us to demonstrate, in addition, that
in the presence of androgen, the WXXLF motif has a significant
but more minor role than the FXXLF motif in mediating the
N/C interaction and in inhibiting the recruitment of TIF2 to
AF2. Unlike the FXXLF motif, WXXLF was not required for the
androgen-induced N/C interaction, consistent with earlier re-
sults that mutating WXXLF alone did not decrease the ligand
dissociation half-time (14). The WXXLF motif is weaker in its
apparent affinity for AF2 and in its ability to inhibit TIF2
binding. The predicted amphipathic -helix and androgen de-
pendence of the WXXLF motif interaction with the ligand bind-
ing domain suggested its interaction with AF2. GST affinity
matrix and two-hybrid peptide interaction assays confirmed
this. The role of the WXXLF motif in inhibiting AR transacti-
vation was evident when mutations in WXXLF increased AR
transactivation of the PSA and probasin enhancer/promoters.
However, in a deletion mutant lacking the NH2-terminal AF1
region, the WXXLF mutant did not overcome the predominant
inhibitory effect of the FXXLF motif on TIF2 recruitment by
AF2.
Homology comparisons support the relative functional im-
portance of the FXXLF and WXXLF binding motifs. FQNLF is
highly conserved among mammals (24–28) (Fig. 6), paralleling
its predominant role in the N/C interaction and in modulating
AF2 accessibility to p160 coactivators. In Japanese eel AR and
goldfish AR, tyrosine (Y) replaces phenylalanine (F) in position
1 of the motif, and in these and rainbow trout AR  and ,
valine (V) replaces leucine (L). These conservative substitu-
tions preserve the predicted amphipathic -helical structure
that characterizes a binding motif for AF2. It is not known,
however, whether an N/C interaction occurs in the AR of these
fish species. In agreement with its less prominent role in the
N/C interaction, WHTLF is conserved in mammals and Xeno-
pus, but in fish is less conserved than FQNLF (Fig. 6). Trypto-
phan (W) is conserved throughout but there is significant se-
quence deviation at other positions such that an amphipathic
-helix is not predicted for the WXXLF motif region in fish AR.
Our previous studies of ligand dissociation rate, two-hybrid
interactions and GST affinity matrix binding suggest an an-
drogen-induced N/C interaction selectively induced by biologi-
cally active androgens (8–10). Moreover, we observed that cer-
tain mutations that cause the androgen insensitivity syndrome
disrupt the N/C interaction without significantly altering an-
drogen binding affinity (9, 10). Nevertheless we lacked evi-
dence for the functional importance of the N/C interaction in
that the MMTV-luciferase reporter was influenced by but did
not require the N/C interaction for activation (10, 14). The
critical role for the N/C interaction in AR transactivation of the
androgen responsive PSA and probasin enhancer/promoters
reported here shows a greater dependence on the N/C interac-
FIG. 6. Sequence homology compar-
isons for the FXXLF and WXXLF mo-
tif regions among vertebrate AR.
Amino acid sequence alignment was per-
formed using MultAlin (36) and is shown
relative to human AR amino acid residues
1–40 and 421–450 (37). GenBankTM ac-
cession numbers for AR sequences from
the species are human, M20132, J30180
(37); collared brown lemur, O97776 (24);
mouse, A35895 (27, 28); Xenopus,
AAC97386 (38); rainbow trout AR,
BAA32784 (39); rainbow trout AR,
BAA32785 (39); Japanese eel AR,
BAA75464 (40); Japanese eel AR,
BAA83805 (40); red seabream, BAA33451
(41); and goldfish, AY090897 (M. Betka,
S. C. Rothberg, and G. V. Callard (2002)).
Shown in red are residues conserved in
the FXXLF and WXXLF motifs. Amino
acid residues in green are conserved
based on amino acid, structure, or charge.
A dash indicates no sequence was re-
ported or gaps were introduced to facili-
tate alignment.
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tion than was required for transactivation of the MMTV and
pGL9 promoters. The increase in transactivation mediated by
a GR chimera with an artificially introduced N/C interaction
demonstrated further the striking stimulatory effect of an N/C
interaction on transactivation of the PSA and probasin enhanc-
er/promoter regions.
Under normal physiological conditions, AR transactivation
appears to be mediated by the NH2-terminal AF1 region be-
tween amino acid residues 142–337. Deletion of AF1 results in
essentially complete loss of AR transactivation of the androgen
responsive enhancer/promoters tested in this study. The in-
crease in transactivation that results from mutating WXXLF in
the absence or presence of TIF2 coexpression requires AF1 and
is also inhibited by mutations in AF2. The results suggest that
the increased transactivation by WXXLF mutants reflects a
synergistic effect between AF1 and AF2 brought about by ex-
posing AF2 to activation by endogenous coactivators such as
TIF2. In agreement with this, the WXXLF motif binds AF2 and
inhibits AF2 mediated transactivation by blocking the binding
of TIF2, albeit to a less extent than does the FXXLF motif. The
data support that the N/C interaction that is mediated by
binding of both the FXXLF and WXXLF motifs to AF2 reduces
p160 coactivator interaction at this site. Inhibition of AF2
coactivation by the androgen-induced N/C interaction renders
AF1 the predominant activation domain in AR unless coacti-
vator expression levels exceed the capacity of the N/C interac-
tion to block coactivator binding.
Several lines of evidence support the predominant role of
AF1 in AR transactivation. The AF2 mutant AR-K720A that
blocks TIF2 binding to AF2 (10) does not decrease AR-mediated
transactivation except in response to TIF2 overexpression. The
agonist-induced N/C interaction mediated by the FXXLF and
WXXLF motifs results in competitive inhibition of p160 coac-
tivator binding at AF2. AF2 preferentially binds the FXXLF
sequence compared with the LXXLL sequences of the p160
coactivators (15). Under normal physiological conditions, p160
coactivator expression was relatively low in benign adult hu-
man prostate when compared with prostate cancer (29). It is
clear that AR transactivation can be increased by TIF2 over-
expression, which enables TIF2 LXXLL motifs to compete suc-
cessfully for interaction with AF2. Thus in situations of high
TIF2 expression such as in prostate cancer (29), AR transacti-
vation may be mediated by both AF1 and AF2. We (10) and
others (30, 31) have reported that TIF2 and other p160 coacti-
vators interact with the AR NH2-terminal domain. In the pres-
ent study using the PSA and probasin enhancer/promoters,
mutations in AF2 abolished TIF2 stimulation of AR transacti-
vation. Thus interaction of overexpressed TIF2 with the AR
NH2-terminal domain was secondary to TIF2 binding to AF2.
In support of this, TIF2m123, which has mutations in the
LXXLL motifs, was inactive in the presence and absence of the
N/C interaction using the PSA, probasin, MMTV, and pGC9-
Luc reporters, indicating that TIF2 interaction with AF2 is
required for AR coactivation. The results with TIF2 contrast
previous reports that GRIP1 and SRC1e interactions with the
AR NH2-terminal domain are sufficient for coactivation of AR
transactivation (30, 31). The differences suggest that p160
coactivators may use different mechanisms to increase AR-
mediated gene activation.
It is not clear what features of the enhancer/promoter re-
gions require the N/C interaction in AR transactivation. A viral
promoter such as MMTV lacks receptor specificity and is acti-
vated by the AR, GR, and the progesterone receptor (32, 33).
Other enhancer/promoters show varying degrees of specificity
for AR transactivation. In our studies, the MMTV, PSA, and
probasin luciferase reporters were activated by AR and GR,
whereas there was little GR transactivation of pGL9. It is well
established that GR stimulates the MMTV promoter (21–23),
whereas the probasin (34, 35) and pGL9 (20) enhancer/pro-
moters are reported to be selectively activated by AR. It was
the PSA, probasin and pGL9 enhancer/promoters that
showed increased transactivation by the GR chimera with an
imposed N/C interaction. At this time there are no evident
predictive features that differentiate these enhancer/promoter
androgen response elements in terms of their sensitivity to the
N/C interaction. We expect that the differences in requiring a
receptor N/C interaction relate to the sequence or organization
of the response elements. Enhancer/promoters of androgen-
regulated genes such as PSA and probasin that have not been
attributed to ancient viral insertions tend to have more widely
spaced response elements compared with viral-derived promot-
ers. An antiparallel AR dimer mediated by the N/C interaction
in the AR dimer could promote folding of genomic DNA in a
way that brings response elements into close proximity and
provide synergy between response elements through this and
mechanisms that remain to be established.
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